Document is current
Any future updates will be listed below
-
Authors
Schito, Paride
Domi, Teuta
Russo, Tommaso
Pozzi, Laura
Falzone, Yuri Matteo
Pipitone, Giovanni Battista
Agosta, Federica
Carrera, Paola
Quattrini, Angelo
Riva, Nilo
Filippi, Massimo https://orcid.org/0000-0002-5485-0479
- License Information
-
More Information
Article History
Received: 29 September 2025
Revised: 12 November 2025
Accepted: 14 November 2025
First Online: 21 November 2025
Declarations
:
: Paride Schito, Teuta Domi, Tommaso Russo, Laura Pozzi, Yuri Matteo Falzone, and Giovanni Battista Pipitone have nothing to disclose. F. Agosta is Associate Editor of NeuroImage: Clinical, has received compensation for consulting services from Eli Lilly and Eisai; speaker honoraria from Biogen Idec, Eli Lilly, Eisai, GE Healthcare, Roche, and Bristol-Myers Squibb, and receives or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council, the EU Joint Programme—Neurodegenerative Disease Research (JPND), and Foundation Research on Alzheimer Disease (France). Paola Carrera, Angelo Quattrini, and Nilo Riva have nothing to disclose. Prof. Filippi is Editor-in-Chief of the Journal of Neurology , Associate Editor of Human Brain Mapping , Neurological Sciences, and Radiology ; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
: All the included PLS patients provided informed consent for the genetic analysis and their participation in a study protocol aimed at establishing genotype–phenotype correlation. The study protocol was approved by the ethics committee of our institute (Protocollo Genotipo-Fenotipo, reference number DSAN 855-A-OS/3).
